Review



cpasstm elisa-based sars-cov-2 surrogate virus neutralization antibody detection test kit  (GenScript corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GenScript corporation cpasstm elisa-based sars-cov-2 surrogate virus neutralization antibody detection test kit
    ( a ) The total anti-S antibodies (including IgG) to the <t>SARS-CoV-2</t> spike protein receptor binding domain (RBD) counts. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.
    Cpasstm Elisa Based Sars Cov 2 Surrogate Virus Neutralization Antibody Detection Test Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cpasstm+elisa-based+sars-cov-2+surrogate+virus+neutralization+antibody+detection+test+kit/pmc08539465-57-3-11?v=GenScript+corporation
    Average 90 stars, based on 1 article reviews
    cpasstm elisa-based sars-cov-2 surrogate virus neutralization antibody detection test kit - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination"

    Article Title: Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

    Journal: Vaccines

    doi: 10.3390/vaccines9101145

    ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor binding domain (RBD) counts. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.
    Figure Legend Snippet: ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor binding domain (RBD) counts. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

    Techniques Used: Binding Assay, Enzyme-linked Immunosorbent Assay, Neutralization

    ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by gender. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts by gender. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.
    Figure Legend Snippet: ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by gender. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts by gender. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

    Techniques Used: Binding Assay, Enzyme-linked Immunosorbent Assay, Neutralization

    ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by age. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) NeuTable 3 and 5 weeks after first vaccination and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.
    Figure Legend Snippet: ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by age. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) NeuTable 3 and 5 weeks after first vaccination and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

    Techniques Used: Binding Assay, Enzyme-linked Immunosorbent Assay, Neutralization



    Similar Products

    cpasstm elisa-based sars-cov-2 surrogate virus neutralization antibody detection test kit  (GenScript corporation)
    90
    GenScript corporation cpasstm elisa-based sars-cov-2 surrogate virus neutralization antibody detection test kit
    ( a ) The total anti-S antibodies (including IgG) to the <t>SARS-CoV-2</t> spike protein receptor binding domain (RBD) counts. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.
    Cpasstm Elisa Based Sars Cov 2 Surrogate Virus Neutralization Antibody Detection Test Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cpasstm+elisa-based+sars-cov-2+surrogate+virus+neutralization+antibody+detection+test+kit/pmc08539465-57-3-11?v=GenScript+corporation
    Average 90 stars, based on 1 article reviews
    cpasstm elisa-based sars-cov-2 surrogate virus neutralization antibody detection test kit - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor binding domain (RBD) counts. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

    Journal: Vaccines

    Article Title: Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

    doi: 10.3390/vaccines9101145

    Figure Lengend Snippet: ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor binding domain (RBD) counts. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

    Article Snippet: The cPass™ ELISA-based SARS-CoV-2 surrogate virus neutralization antibody detection test kit (GenScript Biotech Corporation, Piscataway, NJ, USA), applies an indirect detection method via assessing antibody-mediated inhibition of SARS-CoV-2 RBD binding to the human host receptor angiotensin-converting enzyme 2.

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Neutralization

    ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by gender. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts by gender. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

    Journal: Vaccines

    Article Title: Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

    doi: 10.3390/vaccines9101145

    Figure Lengend Snippet: ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by gender. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts by gender. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

    Article Snippet: The cPass™ ELISA-based SARS-CoV-2 surrogate virus neutralization antibody detection test kit (GenScript Biotech Corporation, Piscataway, NJ, USA), applies an indirect detection method via assessing antibody-mediated inhibition of SARS-CoV-2 RBD binding to the human host receptor angiotensin-converting enzyme 2.

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Neutralization

    ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by age. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) NeuTable 3 and 5 weeks after first vaccination and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

    Journal: Vaccines

    Article Title: Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

    doi: 10.3390/vaccines9101145

    Figure Lengend Snippet: ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by age. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) NeuTable 3 and 5 weeks after first vaccination and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

    Article Snippet: The cPass™ ELISA-based SARS-CoV-2 surrogate virus neutralization antibody detection test kit (GenScript Biotech Corporation, Piscataway, NJ, USA), applies an indirect detection method via assessing antibody-mediated inhibition of SARS-CoV-2 RBD binding to the human host receptor angiotensin-converting enzyme 2.

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Neutralization